AlgiPharma is a research-based biopharmaceutical company that aims to deliver returns to shareholders by developing our technology to generate new therapeutic options leading to improved drug delivery and healthcare through innovation, development, and manufacture of alginate oligosaccharides.
Experienced: The AlgiPharma team has a solid foundation of expertise supported by a broad and active collaboration network with key opinion leaders, front line health care providers, patient organisations, research foundations, and academic centres of excellence.
Unique and Protected: The technology platform is protected by a broad and young IP portfolio with 17 granted patent families, actively managed by a leading European patent and trademark attorney with a renowned international reputation.
Financial Support: AlgiPharma AS has received over 46 million US dollars in grants and non-dilutive funding from Norwegian, UK, European, Australian, US Department of Defence programs, and the Cystic Fibrosis Foundation.
Solid Science: Over 25 peer-reviewed scientific articles support solid technology validation.
Safety: Comprehensive preclinical toxicology portfolio supporting an exemplary safety profile for inhalation administration. Proven safety in human studies (+175 subjects).
Proven API Quality: The API has been produced in two different formulations used in human clinical trials. Other prototype formulations have been tested in pre-clinical studies.
AlgiPharma is a clinical stage pharmaceutical company founded in August 2006, based on research and development carried out by FMC BioPolymer AS and the Biopolymer Foundation at the Norwegian University of Science and Technology in Trondheim, Norway. AlgiPharma Holding AS is a privately owned company registered and domiciled in Norway. All operations are run via its wholly owned subsidiaries in Norway and Australia.
